Why the CRISPR patent verdict isn’t the end of the story
Several institutions are embroiled in a legal dispute over the foundational patent rights to CRISPR-Cas9 gene-editing technology, and it may take years for their competing claims to be resolved (1–4). But even before ownership of the patents is finalized, the institutions behind CRISPR have wasted no time capitalizing on the huge market for this groundbreaking technology by entering into a series of license agreements with commercial enterprises (see the figure). With respect to the potentially lucrative market for human therapeutics and treatments, each of the key CRISPR patent holders has granted exclusive rights to a spinoff or “surrogate” company formed by the institution and one of its principal researchers (5, 6). Although this model, in which a university effectively outsources the licensing and commercialization of a valuable patent portfolio to a private company, is not uncommon in the world of university technology transfer, we suggest it could rapidly bottleneck the use of CRISPR technology to disc
From legal challenges to ongoing experimentation, the story of who owns the rights to CRISPR gene editing is still being written.
Fri 17 Feb 17 from Nature News
Several institutions are embroiled in a legal dispute over the foundational patent rights to CRISPR-Cas9 gene-editing technology, and it may take years for their competing claims to be resolved ...
Thu 16 Feb 17 from Science Now
Just 5 years ago, the community of researchers studying CRISPR, the powerful new genome editing tool, was small. When the first inklings that CRISPR could become a big business emerged, leading ...
Thu 16 Feb 17 from Science Now
In a highly anticipated decision that could sway the fortunes of a handful of biotechnology companies, the federal patent office has turned back a challenge to patents covering a widely used ...
Thu 16 Feb 17 from Phys.org
The US Patent and Trademark Office issues a verdict in legal tussle over rights to genome-editing technology.
Wed 15 Feb 17 from Nature News
The dispute between researchers at UC Berkeley and the Broad Institute over the invention of the powerful gene-editing technique has been decided.
Wed 15 Feb 17 from MIT Technology Review
Last week, the US Patent and Trademarks office handed down a decision in one of the most high-profile patent cases of the century. In a one sentence ruling, an appeals board granted the rights ...
Thu 23 Feb 17 from Gizmodo
Patent court judges released long-awaited decision, but legal battle for CRISPR is just beginning
Thu 16 Feb 17 from CandEN
Health Exclusive agreements with private companies could delay vital research But what still hangs in the air, detailed in a report out today in the journal Science, is ...
Thu 16 Feb 17 from Popular Science
The U.S. patent office has delivered a potentially lucrative victory to bioengineer Feng Zhang of the Broad Institute in Massachusetts, regarding patents for an extraordinarily useful gene-editing ...
Thu 16 Feb 17 from KQED Science